No completed human clinical trials exist yet, though Phase 1 data for the analog CB4211 showed promising metabolic improvements
The enzyme DLD (E3), with FAD as a cofactor, catalyzes that oxidation reaction generating FADH 2
This treatment may not be suitable for all patients, including some older adults or those with complex health conditions
Compounded copycats of the blockbuster drug tirzepatide, the active ingredient in Mounjaro and Zepbound, could possibly contain concerning byproducts
In clinical studies, tirzepatide has led to weight loss and lowered A1C (3-month blood glucose levels) to a normal range." Both Mounjaro and Zepbound are available in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as once-weekly pre-filled injector pens
Common Side Effects (Both Medications) Gastrointestinal Effects (Most Common): Nausea (Zepbound: 25-29%, Wegovy: 24-44%) Diarrhea (Zepbound: 19-21%, Wegovy: 7-30%) Vomiting (Zepbound: 12%, Wegovy: 24%) Constipation (Zepbound: 12-17%, Wegovy: 14-24%) Abdominal pain or discomfort Indigestion and acid reflux General Side Effects: Fatigue or tiredness (approximately 4% of patients) Headache (more common with Wegovy) Dizziness Hair loss (temporary in most cases) Injection Site Reactions: Redness, itching, or bruising at injection site Slightly more common with Zepbound Managing Common Side Effects The good news is that most side effects are: Mild to moderate in severity Most pronounced during the initial weeks of treatment Tend to decrease as your body adjusts to the medication Manageable with proper strategies Practical Tips to Minimize Side Effects: Start Low, Go Slow: Both medications use gradual dose escalation specifically to minimize side effects Dietary Modifications: Eat smaller, more frequent meals
